ArticleFrontiers in oncology2023
Clinical updates on gliomas and implications of the 5th edition of the WHO classification of central nervous system tumors.
Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Metabolic Imaging as Future Technology and Innovation in Brain-Tumour Surgery: A Systematic Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- Machine learning radiomics for H3K27M mutation prediction in gliomas: A systematic review and meta-analysis.Neuroradiology · 2025Pooled it
- Dabrafenib plus trametinib in low-grade versus high-grade gliomas: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- The High Cost of Misdiagnosis: The Challenges of Differentiating Grade-4 Astrocytoma from Glioblastoma in Resource-Constrained Countries.Pakistan journal of medical sciences · 2026Article
- Article
- Bibliometric mapping of glioma classification research through main path, key route, and K-core analyses.Oncotarget · 2026Review
- Surface Proteomic Analysis Reveals the Presence of Noncanonical Cell Membrane Endoplasmic Reticulum Chaperones in High-Grade Gliomas.Journal of proteome research · 2026Article
- Multi-Omics Integration for Advancing Glioma Precision Medicine.Annals of clinical and translational neurology · 2026Review
- A human iPSC-based neural spheroid platform for modelling glioblastoma infiltration using high-content imaging.Scientific reports · 2025Article
- Presenting clinical and radiographic features of diffuse glioma molecular subtypes in accordance with the 2021 CNS5 WHO classification.Neuro-oncology practice · 2025Article
- Improving diagnostic accuracy in preoperative glioma classification: performance of knowledge-enhanced large language models compared with radiologists.NPJ precision oncology · 2025Article
- hsa-miR-144-3p and hsa-miR-4262 are exosomal biomarkers and function as tumor suppressors in HCMV positive brain tumor.Future oncology (London, England) · 2025Observational
- Current Landscape of Preclinical Models for Pediatric Gliomas: Clinical Implications and Future Directions.Cancers · 2025Review
- Can diffusion-based generated magnetic resonance images predict glioma methylation accurately?Quantitative imaging in medicine and surgery · 2025Article
- Engineered nanoparticles as a promising drug delivery system for glioblastoma multiforme treatment.Therapeutic delivery · 2025Review
- Histogram analysis based on DTI and NODDI for differentiating atypical high-grade glioma from primary central nervous system lymphoma.Frontiers in neurology · 2025Article
- Unravelling differences and hallmarks in suspected diffuse low-grade gliomas: a multicentre database study.Brain communications · 2025Article
- TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real-World Study.Cancer medicine · 2025Article
- The double role of GABAergic system in systemic tumors: an updated review.Frontiers in oncology · 2025Review
- Risk Prediction and Management for Central Nervous System Infection After Resection for Gliomas-The 8-Year Experience from a Tertiary Medical Center.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The 5th edition of the World Health Organization (WHO) classification of central nervous system tumors incorporated specific molecular alterations into the categorization of gliomas. The major revision of the classification scheme effectuates significant changes in the diagnosis and management of glioma. This study aimed to depict the clinical, molecular, and prognostic characteristics of glioma and its subtypes according to the current WHO classification. Methods: Patients who underwent surgery for glioma at Peking Union Medical College Hospital during 11 years were re-examined for tumor genetic alterations using next-generation sequencing, polymerase chain reaction-based assay, and fluorescence Results: The enrolled 452 gliomas were reclassified into adult-type diffuse glioma (ntotal=373; astrocytoma, n=78; oligodendroglioma, n=104; glioblastoma, n=191), pediatric-type diffuse glioma (ntotal=23; low-grade, n=8; high-grade, n=15), circumscribed astrocytic glioma (n=20), and glioneuronal and neuronal tumor (n=36). The composition, definition, and incidence of adult- and pediatric-type gliomas changed significantly between the 4th and the 5th editions of the classification. The clinical, radiological, molecular, and survival characteristics of each subtype of glioma were identified. Alterations in CDK4/6, CIC, FGFR2/3/4, FUBP1, KIT, MET, NF1, PEG3, RB1, and NTRK2 were additional factors correlated with the survival of different subtypes of gliomas. Conclusions: The updated WHO classification based on histology and molecular alterations has updated our understanding of the clinical, radiological, molecular, survival, and prognostic characteristics of varied subtypes of gliomas and provided accurate guidance for diagnosis and potential prognosis for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.